We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · July 12, 2021

NECTIN4 Expression Mediates Sensitivity to Enfortumab Vedotin in Urothelial Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Clin. Cancer Res 2021 Jun 09;[EPub Ahead of Print], CE Chu, M Sjöström, EA Egusa, EA Gibb, ML Badura, J Zhu, VS Koshkin, BA Stohr, MV Meng, RS Pruthi, TW Friedlander, Y Lotan, PC Black, SP Porten, FY Feng, J Chou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading